Market Trends of Sulphonamides Industry
This section covers the major market trends shaping the Sulphonamides Market according to our research experts:
Urinary Tract Infection is Expected to Witness Significant Growth During the Forecast Period
Urinary tract infection (UTI) affects the urinary tract. It is one of the most common bacterial infections. It is more common in women than men. UTI is one of the most frequent causes of morbidity and mortality, globally. The prevalence of uncomplicated UTIs is significantly higher compared to recurring, complicated UTIs.
As per the study report published by the European Journal of Medical Research in February 2022, urinary tract infections are highly prevalent in patients with type 2 diabetes. A number of research studies on aging participants showed that the prevalence of urinary tract infections in diabetic Iranian patients increased due to their growing age. Hence, the increasing prevalence of UTI due to the growing elderly population is expected to boost the demand for antimicrobials like sulphonamides and help in the market's growth over the forecast period.
With new research funding for infectious diseases, including UTIs, and the substantial availability of various sulfonamide drug formulations at a reasonable price, the prevalence of complicated UTIs is expected to increase in the future, owing to the rising drug-resistant bacteria and excessive use of antibiotics. A vast majority of physicians prescribe sulphonamides to treat UTI cases, which may also contribute to the growth of the market in the future.
North America is Expected to Register Significant Growth in the Market During the Forecast Period
North America is expected to have significant growth in the market due to growing R&D activities in medical sciences, availability of technologically advanced products, rising use of antibiotics, and the growing elderly population.
The rising incidence of tuberculosis in the region is the key factor driving the market's growth as sulphonamide is used as a potential medicine to treat drug-resistant tuberculosis. For instance, according to the CDC's NTSS, 7,860 tuberculosis cases were reported in 50 US states and the District of Columbia (DC) in 2021. The national incidence of reported tuberculosis cases (cases per 100,000 people) increased by 9.4% in 2021 (2.37) compared to the previous year. As per the same source, in 2021, some of the regions with the highest number of tuberculosis cases were California (1,750), Texas (991), Florida (499), Pennsylvania (166), Ohio (149), and Arizona (129). Thus, widespread tuberculosis in the region needs proper treatment measures, which may drive the demand for sulphonamides in the region.
In North America, the United States is expected to witness notable growth in the sulphonamide market during the forecast period due to the high prevalence and incidence of infectious diseases. According to the article by the CDC published in November 2021, the common cold affects millions of people in the United States each year. On average, adults have cold 2-3 times every year, with children being more at risk. Thus, due to the high burden of bacterial infectious diseases, the United States is expected to hold a major share of the sulphonamides market in North America.
